xCures Revenue and Competitors

xCures is a technology platform that connects advanced cancer patients to the drugs and tests they need. The platform provides a personalized list of treatment options and information about how to access them. The options are curated by expert scientists and oncologists. Patients pay with their data. They sign a HIPAA release giving xCures the right to request their medical records. The records are sent from the treating facility as a PDF or facsimile. The structuring of the data into a summary for use by the patients and their doctors is automated. Pharmaceutical companies make their investigational and existing drugs available on the platform to generate valuable real world evidence (RWE). RWE is used to accelerate the development of new drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. Pharmaceutical companies pay fees to access patient data. The source documents and data are organized so they can be used directly in regulatory submissions to the FDA. Drugs are made available to the patients on the xCures platform through managed access programs. These programs have previously been poorly perceived because there wasn’t a good way to collect data from the participants. xCures prospectively collects this valuable RWE by obtaining the patients’ consent and getting the medical records directly from the doctors and hospitals. There are 610,000 advanced cancer patients in the US, of which less than 50,000 are able to get into clinical trials. xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options. xCures AI algorithms use this data to continuously learn from every patient and optimize options selection for future use. xCures learns from all patients, all physicians, all therapies, all the time.